Company Description
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.
Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms.
Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017.
The company was incorporated in 2011 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Apr 30, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Lyn Baranowski |
Contact Details
Address: 105 W First Street Boston, Massachusetts 02127 United States | |
| Phone | (206) 707-0340 |
| Website | avalynpharma.com |
Stock Details
| Ticker Symbol | AVLN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1540171 |
| CUSIP Number | 05348Y105 |
| ISIN Number | US05348Y1055 |
| Employer ID | 45-2463191 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lyn Baranowski | Chief Executive Officer and Director |
| Douglas Carlson | Chief Financial Officer and Chief Business Officer |
| Melissa Rhodes, Ph.D., D.A.B.T | Chief Operating Officer |
| Howard M. Lazarus, M.D., FCCP | Chief Medical Officer |
| Heather Turner | Director and Board Chair |
| Tiba Aynechi, Ph.D. | Director |
| Jill Carroll | Director |
| Jon Congleton | Director |
| David Friedman, M.D. | Director |
| Kate Haviland | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2026 | SCHEDULE 13D | Filing |
| May 8, 2026 | SCHEDULE 13D | Filing |
| May 7, 2026 | SCHEDULE 13G | Filing |
| May 5, 2026 | SCHEDULE 13G | Filing |
| May 1, 2026 | 8-K | Current Report |
| Apr 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 30, 2026 | 424B4 | Prospectus |
| Apr 29, 2026 | EFFECT | Notice of Effectiveness |
| Apr 29, 2026 | CERT | Certification by an exchange approving securities for listing |
| Apr 29, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |